Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.36 |
| ▸ | CES1 | P23141 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16045071 | 0.81 | ERN1 (0.38) | MAPTCA3CA6CA5ACA9 | |
| SCHEMBL4023120 | 0.79 | MEP1A (0.37) | CES2CES1MAPTCA3CA6 | |
| SCHEMBL374724 | 0.79 | AKR1B1 (0.36) | MAPTCA3CA6CA5ACA9 | |
| SCHEMBL29737879 | 0.79 | MEP1A (0.37) | CES2CES1MAPTCA3CA6 | |
| SCHEMBL28694200 | 0.79 | ALOX15 (0.39) | MAPTLMNAGAASMN1; SMN2TDP1 | |
| SCHEMBL29761144 | 0.79 | AKR1B1 (0.36) | MAPTCA3CA6CA5ACA9 | |
| SCHEMBL29761143 | 0.79 | AKR1B1 (0.36) | MAPTCA3CA6CA5ACA9 | |
| SCHEMBL78147 | 0.77 | ERN1 (0.42) | CES2CES1CA3CA6CA5A | |
| SCHEMBL30368289 | 0.77 | ERN1 (0.42) | CES2CES1CA3CA6CA5A | |
| SCHEMBL24204693 | 0.75 | CA9 (0.32) | MAPTCA3CA6CA5ACA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110563565-A | synthetic method of 3-bromo-6-fluoro-2-methoxybenzaldehyde | 南通大学 | 2019-12-13 | — | — | CN | claimed |
| WO-2025264645-A1 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| EP-4665458-A1 | INHIBITING ALPHA V BETA8 INTEGRIN | Morphic Therapeutic, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4189036-B1 | DIBENZOFURAN AND DIBENZOTHIOPHENE DERIVATIVES | MERCK PATENT GMBH (DE) | 2025-06-18 | — | — | EP | disclosed |
| WO-2025090465-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-05-01 | — | — | WO | disclosed |
| CN-114478447-B | Benzo oxygen-containing ring derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20240294542-A1 | NLRP3 INFLAMMASOME INHIBITOR AND APPLICATION THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2024-09-05 | — | — | US | disclosed |
| US-12071425-B2 | Phenoxy-pyridyl-pyrimidine compounds and methods of use | GENENTECH, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| WO-2024173572-A1 | INHIBITING α vβ8 INTEGRIN | MORPHIC THERAPEUTIC, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
| EP-3849664-B1 | PHENOXY-PYRIDYL-PYRIMIDINE COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2024-06-12 | — | — | EP | disclosed |
| EP-1930396-A1 | Furochroman derivatives | MERCK PATENT GmbH (DE) | 2008-06-11 | — | — | EP | disclosed |
| EP-1713767-A4 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2008-01-16 | — | — | EP | disclosed |
| EP-1713767-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005077892-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-25 | — | — | WO | disclosed |
| EP-1204659-A2 | SEROTONERGIC BENZOFURANS | ELI LILLY AND COMPANY (US) | 2002-05-15 | — | — | EP | disclosed |
| EP-1204654-A1 | BENZOFURYLPIPERAZINES AND BENZOFURYLHOMOPIPERAZINES: SEROTONIN AGONISTS | ELI LILLY AND COMPANY (US) | 2002-05-15 | — | — | EP | disclosed |
| EP-1149085-A1 | AMINOALKYLBENZOFURANS AS SEROTONIN (5-HT(2C)) AGONISTS | ELI LILLY AND COMPANY (US) | 2001-10-31 | — | — | EP | disclosed |
| WO-2001009111-A1 | BENZOFURYLPIPERAZINES AND BENZOFURYLHOMOPIPERAZINES: SEROTONIN AGONISTS | ELI LILLY AND COMPANY (US) | 2001-02-08 | — | — | WO | disclosed |
| WO-2001009122-A2 | SEROTONERGIC BENZOFURANS | ELI LILLY AND COMPANY (US) | 2001-02-08 | — | — | WO | disclosed |
| WO-2000044737-A1 | AMINOALKYLBENZOFURANS AS SEROTONIN (5-HT(2C)) AGONISTS | ELI LILLY AND COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294542-A1 | NLRP3 INFLAMMASOME INHIBITOR AND APPLICATION THEREOF | NLRP3, NLRP1, PYCARD | CES2 4802/4885CES1 2589/4885MAPT 57/4885 |
| US-12071425-B2 | Phenoxy-pyridyl-pyrimidine compounds and methods of use | XBP1, ERN1, ESR2 | CES2 1062/4885CES1 224/4885MAPT 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.